Moderna, Inc. $MRNA Shares Sold by Legal & General Group Plc

Legal & General Group Plc decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 936,970 shares of the company’s stock after selling 64,289 shares during the quarter. Legal & General Group Plc’s holdings in Moderna were worth $27,631,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. MUFG Securities EMEA plc acquired a new stake in shares of Moderna during the 2nd quarter valued at $28,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Moderna during the fourth quarter worth $31,000. Ameriflex Group Inc. boosted its position in shares of Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after purchasing an additional 1,208 shares during the period. Cromwell Holdings LLC increased its stake in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on MRNA. Morgan Stanley set a $33.00 price objective on shares of Moderna in a research note on Friday, May 1st. Citigroup restated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Piper Sandler lifted their price target on Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a report on Monday, February 23rd. Royal Bank Of Canada increased their price objective on Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research note on Monday, May 4th. Finally, Jefferies Financial Group set a $37.00 target price on Moderna and gave the company a “hold” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $35.73.

Moderna Price Performance

Shares of Moderna stock opened at $47.19 on Monday. The firm has a market cap of $18.72 billion, a price-to-earnings ratio of -5.79 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55. The stock has a 50-day simple moving average of $50.24 and a 200-day simple moving average of $42.52.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company’s quarterly revenue was up 260.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.52) EPS. On average, equities research analysts expect that Moderna, Inc. will post -6.49 earnings per share for the current fiscal year.

Insider Activity

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the transaction, the director directly owned 3,924 shares in the company, valued at $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $46.63, for a total value of $264,951.66. Following the sale, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,281 shares of company stock worth $3,280,293. 10.80% of the stock is owned by corporate insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.